Elizabeth Lewiner

Title: Elizabeth Lewiner: Innovator in Pharmaceutical Chemistry

Introduction

Elizabeth Lewiner is a prominent inventor based in Tel Aviv, Israel. She has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of processes for preparing clarithromycin and its intermediates. With a total of 2 patents to her name, her work has had a substantial impact on the pharmaceutical industry.

Latest Patents

Lewiner's latest patents focus on innovative processes for preparing protected silylated clarithromycin oxime, specifically 6-O-methyl-2',4″-bis(trimethylsilyl)-erythromycin A 9-O-(2-methoxyprop-2-yl)oxime, also known as "S-MOP oxime." These patents detail methods for converting this oxime into clarithromycin, emphasizing the use of specific solvents and reagents to achieve optimal results. The processes include reacting a silyl oxime derivative with a methylating agent in the presence of methyl tert-butyl ether, as well as methods for converting the oxime to clarithromycin without additional water addition.

Career Highlights

Elizabeth Lewiner is associated with Teva Pharmaceutical Industries Limited, a leading global pharmaceutical company. Her work at Teva has allowed her to focus on innovative solutions in drug formulation and synthesis. Her contributions have been recognized within the industry, showcasing her expertise in pharmaceutical processes.

Collaborations

Throughout her career, Lewiner has collaborated with notable colleagues, including Igor Lifshitz and Iiya Avrutov. These partnerships have fostered a collaborative environment that enhances the development of innovative pharmaceutical solutions.

Conclusion

Elizabeth Lewiner is a key figure in pharmaceutical innovation, with her patents reflecting her dedication to advancing drug development processes. Her work continues to influence the field, making her a valuable asset to the pharmaceutical community.